Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

about

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

Item

http://www.wikidata.org/entity/Q44965471

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

@en

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

@nl

type

Item

label

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

@en

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

@nl

prefLabel

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

@en

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

@nl

P1476

Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients.

@en

P2093

Anders Mellemgaard

http://www.w3.org/2001/XMLSchema#string

Per Hartvig Honoré

http://www.w3.org/2001/XMLSchema#string

Sigrid Jóhansdóttir Joensen

http://www.w3.org/2001/XMLSchema#string

Steen Honoré Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Management of pleural effusion, empyema, and lung abscess

A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours

Ways to fit a PK model with some data below the quantification limit.

Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model.

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

Handling data below the limit of quantification in mixed effect models.

Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues

Pharmacokinetic variability of anticancer agents.

Standard deviations and standard errors

P2888

s00280-014-2485-x

P304

349-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-014-2485-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michelle L. Olsen

P577

2014-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24934863

http://www.w3.org/2001/XMLSchema#string